ARRIVENT BIOPHARMA IN

34,19

08-ноября-24 14:59:57

15 мин. задержка

Акции

-1,44

-4,04%

Сегодняшний диапазон

33,17 - 36,37

ISIN

N/A

Источник

NASDAQ

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

09 сен 2024 11:05:00 Источник Nasdaq GlobeNewswire
ArriVent BioPharma Reports Second Quarter 2024 Financial Results

14 авг 2024 15:01:00 Источник Nasdaq GlobeNewswire
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

12 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

05 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
ArriVent Appoints John Hohneker, M.D., to its Board of Directors

16 май 2024 15:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.